These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 29474637

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Telomerase reverse transcriptase promoter mutations in cancers derived from multiple organ sites among middle eastern population.
    Siraj AK, Bu R, Iqbal K, Parvathareddy SK, Siraj N, Siraj S, Diaz MRF, Rala DR, Benito AD, Sabido MA, Al-Rasheed M, Al-Obaisi KAS, Al-Haqawi W, Victoria IG, Al Balawy W, Abedalthagafi M, Wakil SM, Ajarim D, Mohammed S, Alhussain T, Tulbah A, Al-Badawi IA, Al-Dayel F, Al-Kuraya KS.
    Genomics; 2020 Mar; 112(2):1746-1753. PubMed ID: 31669704
    [Abstract] [Full Text] [Related]

  • 23. The clinical value of surgeons' efforts of preventing intraoperative tumor rupture in stage I clear cell carcinoma of the ovary: A Korean multicenter study.
    Suh DH, Park JY, Lee JY, Kim BG, Lim MC, Kim JW, Bae DS, Park SY, Nam JH, Kim K, No JH, Kim YB.
    Gynecol Oncol; 2015 Jun; 137(3):412-7. PubMed ID: 25868967
    [Abstract] [Full Text] [Related]

  • 24. TERT promoter mutations are associated with poor prognosis in cutaneous squamous cell carcinoma.
    Campos MA, Macedo S, Fernandes M, Pestana A, Pardal J, Batista R, Vinagre J, Sanches A, Baptista A, Lopes JM, Soares P.
    J Am Acad Dermatol; 2019 Mar; 80(3):660-669.e6. PubMed ID: 30165166
    [Abstract] [Full Text] [Related]

  • 25. Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features.
    Zuberi M, Mir R, Das J, Ahmad I, Javid J, Yadav P, Masroor M, Ahmad S, Ray PC, Saxena A.
    Clin Transl Oncol; 2015 Oct; 17(10):779-87. PubMed ID: 26063644
    [Abstract] [Full Text] [Related]

  • 26. Proposing a molecular classification associated with hypercoagulation in ovarian clear cell carcinoma.
    Tamura R, Yoshihara K, Matsuo K, Yachida N, Miyoshi A, Takahashi K, Sugino K, Yamaguchi M, Mori Y, Suda K, Ishiguro T, Okuda S, Motoyama T, Nakaoka H, Kikuchi A, Ueda Y, Inoue I, Enomoto T.
    Gynecol Oncol; 2021 Nov; 163(2):327-333. PubMed ID: 34452748
    [Abstract] [Full Text] [Related]

  • 27. Suppressor-type TERT mutations associated with recurrence in ovarian clear cell carcinoma.
    Kobayashi T, Nishikimi K, Mitsuhashi A, Piao H, Matsuoka A, Otsuka S, Tate S, Shozu M, Usui H.
    Genes Chromosomes Cancer; 2023 Aug; 62(8):471-476. PubMed ID: 36710084
    [Abstract] [Full Text] [Related]

  • 28. Endometriosis-associated Ovarian Cancers.
    Anglesio MS, Yong PJ.
    Clin Obstet Gynecol; 2017 Dec; 60(4):711-727. PubMed ID: 28990985
    [Abstract] [Full Text] [Related]

  • 29. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.
    Kurtis B, Zhuge J, Ojaimi C, Ye F, Cai D, Zhang D, Fallon JT, Zhong M.
    Ann Diagn Pathol; 2016 Apr; 21():7-11. PubMed ID: 27040924
    [Abstract] [Full Text] [Related]

  • 30. Clinicopathological and Prognostic Values of Telomerase Reverse Transcriptase (TERT) Promoter Mutations in Ovarian Clear Cell Carcinoma for Predicting Tumor Recurrence, Platinum Resistance and Survival.
    Yoo H, Kim HS.
    Cancer Genomics Proteomics; 2023 Apr; 20(6):626-636. PubMed ID: 37889060
    [Abstract] [Full Text] [Related]

  • 31. Prognostic value of histological type in stage IV ovarian carcinoma: a retrospective analysis of 223 patients.
    Mizuno M, Kajiyama H, Shibata K, Mizuno K, Kawai M, Nagasaka T, Kikkawa F.
    Br J Cancer; 2015 Apr 14; 112(8):1376-83. PubMed ID: 25867257
    [Abstract] [Full Text] [Related]

  • 32. Stomatin-like protein 2 is overexpressed in epithelial ovarian cancer and predicts poor patient survival.
    Sun F, Ding W, He JH, Wang XJ, Ma ZB, Li YF.
    BMC Cancer; 2015 Oct 20; 15():746. PubMed ID: 26487491
    [Abstract] [Full Text] [Related]

  • 33. Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations.
    Palsgrove DN, Taheri D, Springer SU, Cowan M, Guner G, Mendoza Rodriguez MA, Rodriguez Pena MDC, Wang Y, Kinde I, Ricardo BFP, Cunha I, Fujita K, Ertoy D, Kinzler KW, Bivalacqua TJ, Papadopoulos N, Vogelstein B, Netto GJ.
    Hum Pathol; 2019 Mar 20; 85():1-9. PubMed ID: 30447301
    [Abstract] [Full Text] [Related]

  • 34. Prevalence of promoter mutations in the TERT gene in oral cavity squamous cell carcinoma.
    Chang KP, Wang CI, Pickering CR, Huang Y, Tsai CN, Tsang NM, Kao HK, Cheng MH, Myers JN.
    Head Neck; 2017 Jun 20; 39(6):1131-1137. PubMed ID: 28230921
    [Abstract] [Full Text] [Related]

  • 35. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma.
    Tsuchiya A, Sakamoto M, Yasuda J, Chuma M, Ohta T, Ohki M, Yasugi T, Taketani Y, Hirohashi S.
    Am J Pathol; 2003 Dec 20; 163(6):2503-12. PubMed ID: 14633622
    [Abstract] [Full Text] [Related]

  • 36. Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma.
    Casuscelli J, Becerra MF, Manley BJ, Zabor EC, Reznik E, Redzematovic A, Arcila ME, Tennenbaum DM, Ghanaat M, Kashan M, Stief CG, Carlo M, Voss MH, Feldman DR, Motzer RJ, Chen Y, Reuter VE, Coleman JA, Russo P, Hsieh JJ, Hakimi AA.
    Eur Urol Focus; 2019 Jul 20; 5(4):642-649. PubMed ID: 28951115
    [Abstract] [Full Text] [Related]

  • 37. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
    Allory Y, Beukers W, Sagrera A, Flández M, Marqués M, Márquez M, van der Keur KA, Dyrskjot L, Lurkin I, Vermeij M, Carrato A, Lloreta J, Lorente JA, Carrillo-de Santa Pau E, Masius RG, Kogevinas M, Steyerberg EW, van Tilborg AA, Abas C, Orntoft TF, Zuiverloon TC, Malats N, Zwarthoff EC, Real FX.
    Eur Urol; 2014 Feb 20; 65(2):360-6. PubMed ID: 24018021
    [Abstract] [Full Text] [Related]

  • 38. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
    Melamed A, Manning-Geist B, Bregar AJ, Diver EJ, Goodman A, Del Carmen MG, Schorge JO, Rauh-Hain JA.
    Gynecol Oncol; 2017 Nov 20; 147(2):250-256. PubMed ID: 28822556
    [Abstract] [Full Text] [Related]

  • 39. TERT promoter hotspot mutations in breast cancer.
    Shimoi T, Yoshida M, Kitamura Y, Yoshino T, Kawachi A, Shimomura A, Noguchi E, Yunokawa M, Yonemori K, Shimizu C, Kinoshita T, Ichimura K, Fukuda T, Fujiwara Y, Tamura K.
    Breast Cancer; 2018 May 20; 25(3):292-296. PubMed ID: 29222734
    [Abstract] [Full Text] [Related]

  • 40. Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival.
    Davidson B, Trope' CG, Wang TL, Shih IeM.
    Gynecol Oncol; 2006 Dec 20; 103(3):814-9. PubMed ID: 16844205
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.